Humanigen's (HGEN) COVID Drug Likely to Win EUA Approval - Jefferies
Tweet Send to a Friend
Jefferies analyst Biren Amin reiterated a Buy rating and $40.00 price target on Humanigen (NASDAQ: HGEN) on the belief that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


